OPTIMAL phase III trial
PFS was significantly longer in erlotinib-treated Chinese patients with EGFR Mut+ NSCLC compared with that of patients treated with standard chemotherapy. Erlotinib was also better tolerated.1,2
Study design and endpoints1
- OPTIMAL was a randomised phase III trial that took place across 22 centres in China.
- The trial compared erlotinib versus standard chemotherapy as first-line treatment for EGFR Mut+ NSCLC.
Key Results
Efficacy2
Patients receiving erlotinib had longer PFS than patients receiving chemotherapy.
Safety1
Patients treated with erlotinib experienced fewer treatment related severe AEs, fewer grade 3/4 AEs and fewer dose reductions due to AEs than patients treated with chemotherapy.
Please click here for further safety data
- OPTIMAL: summary of safety data1
- OPTIMAL: most common adverse events reported in 3% of patients or more in either treatment group1